Protagonist Therapeutics (PTGX) Invested Capital (2018 - 2023)

Protagonist Therapeutics (PTGX) has 6 years of Invested Capital data on file, last reported at $10000.0 in Q2 2023.

• For the quarter ending Q2 2023, Invested Capital fell 87.5% year-over-year to $10000.0; the trailing twelve-month figure through Mar 2024 stood at $10000.0 (down 95.07% YoY), and the FY2022 full-year result was $69000.0, down 92.32% from the prior year.
• Invested Capital fell to $10000.0 in Q2 2023, from $22000.0 in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $11.4 million in Q2 2021 to a low of $10000.0 in Q2 2023.
• A 5-year average of $2.8 million and a median of $1.0 million in 2019 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital jumped 1036.19% in 2021 and slumped 99.3% in 2022, its largest moves.
• Tracing PTGX's Invested Capital over 5 years: stood at $10.0 million in 2019, then plunged by 72.68% to $2.7 million in 2020, then slumped by 67.09% to $899000.0 in 2021, then tumbled by 92.32% to $69000.0 in 2022, then sank by 85.51% to $10000.0 in 2023.
• Business Quant data shows PTGX's Invested Capital at $10000.0 in Q2 2023, $22000.0 in Q1 2023, and $69000.0 in Q4 2022.